Abbott Laboratories has agreed to pay $670 million to resolve approximately 2,000 lawsuits involving its specialty preterm infant formulas, according to a settlement announced on August 21, 2026.
The settlement follows a series of legal challenges and a previous $495 million verdict, marking a significant financial resolution for the company regarding its product safety claims.
Abbott continues to maintain the safety of its products, but the payout aims to mitigate further legal uncertainty and potential reputational damage in the healthcare market.